Corrigendum corrigendum to “ utilisation trend of long-acting insulin analogues including biosimilars across europe: findings and implications ”

HIGHLIGHTS

• who: Corrigendum and colleagues from the Strathclyde Institute University of Strathclyde, Glasgow , RE, UK have published the Article: Corrigendum Corrigendum to u201c Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications u201d, in the Journal: BioMed Research International

SUMMARY

Received 8 August 2022; Accepted 8 August 2022; Published % Insulin glargine 300 IU/ml Year Latvia Norway Slovenia Bosnia and Herzegovina Hungary Lithuania Poland Spain (Catalonia) Albania Czech republic Italy Malta Scotland Sweden Austria Estonia % Insulin glargine biosimilar Year Bosnia and herzegovina Hungary Norway Slovenia Catalonia Italy Bulgaria Czech . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or E-mail:

If you don't have an account, you can create one here.